Genomic testing has changed how healthcare is delivered, but while there are ~2 million new cases of cancer diagnosed in the US each year, only a small fraction of those are tested due to the cost, complexity, and lengthy workflows of existing platforms. At Pleno, we reimagined how genomic testing could be done and have built an instrument platform from the ground up to unlock the vast market potential of clinical genomics.

This holds true for more than just oncology. In fact, for all applications where genomics has been shown to improve the quality of care, penetration has been limited, leaving large, untapped markets.

While Next Generation Sequencing (NGS) ushered in a new era of personalized medicine, unlocking the genome to drive improved outcomes, the costs have remained prohibitive. Even though sequencing costs continue to decline, the challenge remains that sequencing costs are only a fraction of the total cost associated with going from a patient sample to a recommended therapy. Total cost, turnaround time, and workflow are all critical to drive uptake. Other enabling tools like PCR and Microarrays face similar challenges that limit their growth potential and market penetration.